An announcement on partners to collaborate in the TRANSFORM trial was made today during the American Heart Association’s (AHA) 2023 Scientific Sessions. Data from the randomized control trial will advance evidence for evaluation and treatment of heart disease by studying actual disease: atherosclerosis.
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 valdostadailytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from valdostadailytimes.com Daily Mail and Mail on Sunday newspapers.
In a consensus statement, the Canadian Cardiovascular Society defines four stages of acute atherothrombotic myocardial infarction based on tissue injury severity.
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.